UroGen Pharma Ltd. - Ordinary Shares (URGN)
URGN moved a median of +0.13% 30 minutes after news, and +0.33% by the close. How URGN actually reacts to news — the realized, point-in-time move the market made, measured across 664 labeled events over the last three years with zero look-ahead.
URGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 657 |
| 30-min | +0.13% | 53% | 659 |
| 60-min | +0.25% | 54% | 661 |
| to close | +0.33% | 55% | 660 |
| Middle 50% of URGN reactions | -1.00% to +2.05% |
|---|---|
| Median reaction (30-min) | +0.13% |
| Measured reactions | 664 |
Half of all UroGen Pharma Ltd. - Ordinary Shares news events land between -1.00% and +2.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How URGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 16 | -1.00% | 19% | -3.26% |
| Rating reiterations | 117 | +0.33% | 54% | +0.41% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how URGN ranks against every other measured name →
That’s how URGN usually reacts — get an email when it moves on news →Email me when URGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to URGN's baseline. Nothing else.
Recent URGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.76% | -1.01% | |
| UroGen Pharma to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +3.67% | +0.93% | |
| Form 8-K UroGen Pharma Ltd. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | -5.85% | |
| IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies | Press release | PR Newswire | -1.77% | -5.85% | |
| UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline | Press release | GlobeNewswire | -1.77% | -5.85% | |
| UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC | Press release | GlobeNewswire | +0.20% | +1.30% | |
| Form 10-Q UroGen Pharma Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.10% | +10.10% | |
| Form 8-K UroGen Pharma Ltd. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +2.10% | +10.10% | |
| UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights | Press release | GlobeNewswire | +2.10% | +10.10% | |
| UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026 | Press release | GlobeNewswire | +0.05% | -1.58% | |
| UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103 | Press release | GlobeNewswire | -1.77% | +1.84% | |
| UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer | Press release | GlobeNewswire | +1.15% | +1.77% | |
| Form 8-K UroGen Pharma Ltd. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | +0.88% | |
| UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.05% | -1.97% | |
| Form 8-K UroGen Pharma Ltd. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | +2.01% | -1.38% | |
| UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution | Press release | GlobeNewswire | +2.01% | -1.38% | |
| UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | +2.01% | -1.38% | |
| Form ARS UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.09% | -1.95% | |
| UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC | Press release | GlobeNewswire | +0.00% | -1.64% | |
| ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial | Press release | GlobeNewswire | -0.91% | +3.83% | |
| UroGen Pharma to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -1.63% | +0.68% | |
| Form 10-Q UroGen Pharma Ltd. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.15% | +4.08% | |
| Form 8-K UroGen Pharma Ltd. For: May 06 | SEC filing · Form 8-K | SEC EDGAR | +2.15% | +4.08% | |
| UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights | Press release | GlobeNewswire | +2.15% | +4.08% | |
| Form DEF 14A UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +3.26% | -2.75% | |
| UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 | Press release | GlobeNewswire | +0.08% | -2.79% | |
| Form PRE 14A UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form PRE | SEC EDGAR | -0.79% | +9.83% | |
| UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer | Press release | GlobeNewswire | -2.25% | -2.30% | |
| Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI | Press release | GlobeNewswire | -2.00% | +0.00% | |
| UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence | Press release | GlobeNewswire | +0.79% | -2.64% | |
| UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.09% | -0.99% | |
| Form 10-K UroGen Pharma Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -8.31% | -12.19% | |
| Form 8-K UroGen Pharma Ltd. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -8.31% | -12.19% | |
| Form 8-K UroGen Pharma Ltd. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -8.31% | -12.19% | |
| UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors | Press release | GlobeNewswire | -8.31% | -12.19% | |
| UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -8.31% | -12.19% | |
| ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC | Press release | GlobeNewswire | +1.23% | +2.60% | |
| UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +1.09% | -1.76% | |
| UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 | Press release | GlobeNewswire | +2.45% | +0.63% | |
| UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit | Press release | GlobeNewswire | +2.07% | +2.27% | |
| Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy | Press release | GlobeNewswire | -2.88% | -2.04% | |
| UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.54% | -3.32% | |
| UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +3.15% | +2.78% | |
| Form 10-Q UroGen Pharma Ltd. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.98% | +28.77% | |
| Form 8-K UroGen Pharma Ltd. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +2.98% | +28.77% | |
| Form S-3ASR UroGen Pharma Ltd. | SEC filing · Form S-3ASR | SEC EDGAR | -1.79% | +2.74% | |
| Form S-8 UroGen Pharma Ltd. | SEC filing · Form S-8 | SEC EDGAR | -1.79% | +2.74% | |
| UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial | Press release | GlobeNewswire | +2.98% | +28.77% | |
| UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum | Press release | GlobeNewswire | +2.98% | +28.77% | |
| UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference | Press release | GlobeNewswire | +0.00% | -2.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the URGN section they belong to.
Where else URGN is measured.
URGN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PolarityTE, Inc. (PTE) | 670 | -0.62% | 38% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 664 | -0.07% | 48% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 660 | 0.00% | 47% |
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is UroGen Pharma Ltd. - Ordinary Shares's median reaction calculated?
Every labeled URGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 664 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 53% of URGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does URGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.